Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acazicolcept - Alpine Immune Sciences

Next Previous
Drug Profile

Acazicolcept - Alpine Immune Sciences

Alternative Names: Acazicolceptum; ALPN 101; CD28/ICOS antagonist - Alpine; Dual CD28/ICOS inhibitor - Alpine Immune Sciences; ICOS/CD28 antagonist - Alpine; ICOS/CD28-antagonist-Alpine-Immune-Sciences

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alpine Immune Sciences
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Immunoglobulin fragments; Immunotherapies; Proteins; Recombinant fusion proteins
  • Mechanism of Action CD28 antigen inhibitors; Inducible T-cell co-stimulator protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Preclinical Arthritis; Type 1 diabetes mellitus; Uveitis
  • No development reported Autoimmune disorders; Connective tissue disorders; Graft-versus-host disease; Haemophagocytic lymphohistiocytosis; Inflammation; Inflammatory bowel diseases; Multiple sclerosis; Psoriatic arthritis; Sjogren's syndrome

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (Parenteral)
  • 28 Dec 2023 No recent reports of development identified for preclinical development in Connective-tissue-disorders in USA (Parenteral)
  • 28 Dec 2023 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top